Inve India ▾

Tatva Chintan Pharma Chem share price & results

Tatva Chintan Pharma Chem Limited· Chemicals· Commodities

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Manufactures phase-transfer catalysts, structure-directing agents, electrolyte salts, pharma/agro chemicals.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue217 ₹ crore+75.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin19.0 %+1.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit21.0 ₹ crore+110.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity7.74 %+4.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-16.40 %−3.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)49.20 %+34.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

4 of 10 judged targets kept · 15 open · verdicts reflect calls analysed to Q1 FY27.

Tatva Chintan Pharma Chem Limited management guidance track record on Inve: 25 targets tracked across analysed earnings calls (4 achieved, 6 missed, 15 open).

TargetOriginal wordingSaidLatest callVerdict
FY26 Revenue Growthupward of 25%
Call transcript, Q1 FY26 · 24 Jul 2025		Q1 FY26Q1 FY27:Promise relates to a completed fiscal year. No new updates.
Call transcript, Q1 FY27 · 17 Jul 2026		Achieved*
SDA Volume Growth40% to 70%
Call transcript, Q1 FY26 · 24 Jul 2025		Q1 FY26Q1 FY27:Promise relates to a completed fiscal year. No new updates.
Call transcript, Q1 FY27 · 17 Jul 2026		Ghosted
Semiconductor Commercializationslow commercialization to begin in 2027, full-scale by 2029
Call transcript, Q1 FY26 · 24 Jul 2025		Q1 FY26Q1 FY27:we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028.
Call transcript, Q1 FY27 · 17 Jul 2026		Delayed

Source: Inve Guidance Tracker for Tatva Chintan Pharma Chem Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Tatva Chintan Pharma Chem Limited's 25 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 22 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,605.4 +2.42% · +₹37.9

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +19.1% 1Y

₹1.0k₹1.2k₹1.4k₹1.6k₹1.8k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 21 Jan 2026Q4 FY26 — 15 May 2026Q1 FY27 — 17 Jul 2026

1Y: ₹1,347.9 on 24 Oct 2025 → ₹1,605.4. High ₹1,991.2 (7 Oct 2026), low ₹1,052.4 (30 Mar 2026).

Previous close
₹1,567.5
Market cap
₹3.7k Cr
52-week range
₹1,052.4 – ₹1,991.2
One year
+18.17%
Price to earnings (TTM to Sept 2026)
58.21×
Return on equity (TTM to Sept 2026)
7.74%

Overview

Symbol
NSE:TATVA
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What Tatva Chintan Pharma Chem Limited does

Based on the company's own presentations, annual report and earnings calls.

Tatva Chintan Pharma Chem is an integrated specialty chemicals manufacturer operating across the value chain, producing Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA) used in zeolite synthesis, Electrolyte Salts and Solutions (ESS) for super-capacitor batteries, and Pharmaceutical & Agrochemical Intermediates and other specialty chemicals (PASC) such as Glymes. It sells to pharmaceutical, agrochemical, automotive, electronics and energy-storage industries, earning through direct manufacture and sale of these chemicals rather than contract/tolling work alone. The company uses proprietary process technologies including conventional synthesis, electrolysis and continuous flow chemistry, and supports its global customer base through wholly-owned overseas subsidiaries in the USA and Netherlands.

Segments

  • Phase Transfer Catalyst (PTC)
  • Structure Directing Agents (SDA)
  • Electrolyte Salts and Solutions (ESS)
  • Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC)
Manufacturing plants
2 (Ankleshwar and Dahej SEZ, Gujarat)
Combined installed capacity
791 KL reactor capacity and 39 assembly lines (as of 31 Mar 2026)
R&D center
DSIR-approved, 36,000 sq. ft. facility in Vadodara with a team of 56, including 26 senior scientists
Market position - SDA
2nd largest manufacturer of SDAs for zeolites globally; largest commercial supplier in India
Market position - PTC
One of India's leading producers with the widest range of PTCs; among key producers globally
Market position - Electrolyte Salts
Largest producer of electrolyte salts for super-capacitor batteries in India
Founded 1996Employees 679 (31 March 2025) Company website

How the price took the results

close before → close after

Q1 FY27
+0.7%
17 Jul
Q4 FY26
−4.9%
16 May
Q3 FY26
+0.9%
21 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Tatva Chintan Pharma Chem Limited

Free account: one company. Everything above stays public.

Write why you follow Tatva Chintan Pharma Chem Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse Tatva Chintan Pharma Chem Limited

Guides on how to read this kind of business and the numbers that matter.